

Marcello Maresca

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7562227/marcello-maresca-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

937
citations

11
h-index

27
g-index

27
ext. papers

1,233
ext. citations

15.1
avg, IF

4.05
L-index

#	Paper	IF	Citations
24	DNA Repair Pathways in the Context of Therapeutic Genome Editing 2022 , 177-192		
23	DNA Base Editing Strategies for Genome Editing 2022 , 193-202		
22	Historical Overview of Genome Editing from Bacteria to Higher Eukaryotes 2022 , 9-17		
21	Specificity of CRISPR-Cas9 Gene Editing 2022 , 289-312		
20	Harnessing DSB repair to promote efficient homology-dependent and -independent prime editing.. <i>Nature Communications</i> , 2022 , 13, 1240	17.4	0
19	Genome Editing in Drug Discovery 2022 , 3-7		
18	Utilizing CRISPR/Cas9 Technologies for in vivo Disease Modeling and Therapy 2022 , 93-110		
17	CRISPR Cas 2022 , 19-46		
16	Extensive transcription mis-regulation and membrane defects in AdipoR2-deficient cells challenged with saturated fatty acids. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021 , 1866, 158884	5	5
15	Correction of a urea cycle defect after ex vivo gene editing of human hepatocytes. <i>Molecular Therapy</i> , 2021 , 29, 1903-1917	11.7	3
14	Universal toxin-based selection for precise genome engineering in human cells. <i>Nature Communications</i> , 2021 , 12, 497	17.4	12
13	Axl receptor tyrosine kinase is a regulator of apolipoprotein E. <i>Molecular Brain</i> , 2020 , 13, 66	4.5	5
12	Improving Precise CRISPR Genome Editing by Small Molecules: Is there a Magic Potion?. <i>Cells</i> , 2020 , 9,	7.9	17
11	Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery. <i>Nature Communications</i> , 2020 , 11, 4903	17.4	22
10	Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq. <i>Science</i> , 2019 , 364, 286-289	33.3	180
9	In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. <i>BMC Biology</i> , 2019 , 17, 4	7.3	34
8	Decoding non-random mutational signatures at Cas9 targeted sites. <i>Nucleic Acids Research</i> , 2018 , 46, 8417-8434	20.1	57

7	NKX6.1 induced pluripotent stem cell reporter lines for isolation and analysis of functionally relevant neuronal and pancreas populations. <i>Stem Cell Research</i> , 2018 , 29, 220-231	1.6	14
6	BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B. <i>BMC Biology</i> , 2018 , 16, 150	7.3	28
5	In vivo CRISPR editing with no detectable genome-wide off-target mutations. <i>Nature</i> , 2018 , 561, 416-419	30.4	202
4	Functional Gut Microbiota Remodeling Contributes to the Caloric Restriction-Induced Metabolic Improvements. <i>Cell Metabolism</i> , 2018 , 28, 907-921.e7	24.6	111
3	Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. <i>Genome Research</i> , 2013 , 23, 539-46	9.7	235
2	ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment		1
1	Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq		11